Gene patents - A time to balance access and incentives

Trends in Biotechnology

Volumn 14, Issue 8, 1996, Pages 298-302

  Caskey, C Thomas ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT PROTEIN;

BIOTECHNOLOGY; DATA BASE; DNA SEQUENCE; DRUG INDUSTRY; GENE SEQUENCE; GENE STRUCTURE; MEDICAL RESEARCH; PATENT; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 0030218159     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-7799(96)10039-1     Document Type: Article

References (14)

1. 1 Anon. (1993) Pharmaceutical R&D: Costs, Risks and Rewards, US Office of Technology Assessments
2. 2 Fritsch, E. F., Lawn, R. M. and Maniatis, T. (1980) Cell 19, 959-972
3. 3 McGregor, M. L. (1992) Biotechnology Law Report 127
4. 4 Biotechnology Newswatch 21 February 1994, p. 1. McGraw-Hill Inc., USA
5. 5 Caskey, C. T. (1995) Chem. Ind. 20, 852
6. 6 Kishimoto, T., Taga, T. and Akira, S. (1994) Cell 76, 253-262
7. 7 Leach, F. S. et al. (1993) Cell 75, 1215-1225
8. 8 Miki, Y. et al. (1994) Science 266, 66-71
9. 9 Tartaglia, L. A. et al. (1995) Cell 83, 1263-1271
10. 10 Stephens, T. et al. (1995) Nature 377, 530-532
11. 11 Williamson, A. R., Elliston, K. O. and Sturchio, J. L. (1995) J. Natl Inst. Health Res. 7, 61-63
12. 12 Cohen, D., Chumakov, I. and Weissenbach, J. (1995) Nature 366, 698-701
13. 13 Hudson, T. J. et al. (1995) Science 270, 1945-1954
14. 14 Dickson, D. (1995) Nature 378, 425